司美格鲁肽，实际上只是模仿了身体内置的减肥机制

Core Viewpoint - The emergence of GLP-1 receptor agonists provides a solution to the dual challenges of obesity and diabetes, breaking the vicious cycle between the two conditions [2][4]. Group 1: Understanding GLP-1 Receptor Agonists - GLP-1 is a crucial incretin hormone that regulates blood sugar levels by promoting insulin secretion, inhibiting glucagon release, and delaying gastric emptying, while also suppressing appetite [4]. - The first GLP-1 receptor agonist, exenatide, was developed from the saliva of the Gila monster, and subsequent drugs like liraglutide and semaglutide have been introduced with improved efficacy and dosing frequency [5][6]. Group 2: Efficacy of Liraglutide - Liraglutide has been shown to effectively control blood sugar levels and promote weight loss in both diabetic and non-diabetic obese patients, leading to its FDA approval for diabetes management in 2009 [6][9]. - Clinical trials demonstrated that participants using liraglutide lost significant weight compared to those on placebo, with reductions of up to 7.2 kg over 20 weeks [7][8]. Group 3: Semaglutide as a New Generation Drug - Semaglutide, introduced in 2017, allows for weekly injections and has shown to reduce body weight by an average of 15% in clinical trials, significantly outperforming previous weight loss medications [10][12]. - The STEP trials confirmed semaglutide's effectiveness in weight management, with participants achieving an average weight loss of 14.9% and improvements in body composition [12][14]. Group 4: Future Prospects - Oral formulations of semaglutide are being explored, showing promising results in managing blood sugar and weight, although currently limited to diabetes treatment [16][19]. - Ongoing studies continue to validate the safety and efficacy of semaglutide, with significant weight loss observed in various patient populations, indicating its potential as a leading treatment for obesity [20].